Baird Maintained Idera Pharmaceuticals (NASDAQ:IDRA) As a “Outperform”; They Now Have a Price Target Of $4

June 13, 2018 - By marketbeat

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Logo

Investors sentiment decreased to 1.57 in Q1 2018. Its down 2.32, from 3.89 in 2017Q4. It dropped, as 12 investors sold Idera Pharmaceuticals, Inc. shares while 25 reduced holdings. 21 funds opened positions while 37 raised stakes. 91.28 million shares or 35.83% less from 142.24 million shares in 2017Q4 were reported.

Bnp Paribas Arbitrage Sa accumulated 0% or 28,765 shares. Capstone Limited Liability owns 424,597 shares for 0.01% of their portfolio. Meeder Asset Mngmt, Ohio-based fund reported 685 shares. State Common Retirement Fund invested in 136,100 shares or 0% of the stock. Moreover, Prudential has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 51,410 shares. Us National Bank De stated it has 4,836 shares or 0% of all its holdings. Pnc Financial Gp reported 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). One Trading Lp has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 120,107 shares. State Board Of Administration Of Florida Retirement Sys invested in 19,240 shares. Bluefin Trading Ltd Co has invested 0.02% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). D E Shaw And Co holds 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) or 25,500 shares. Tiaa Cref Invest Mgmt Lc invested in 0% or 289,728 shares. The Germany-based Deutsche Commercial Bank Ag has invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Bancorp Of New York Mellon invested 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Utah-based Wasatch Advisors has invested 0.01% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA).

Since December 13, 2017, it had 0 insider buys, and 1 insider sale for $480,000 activity.

Idera Pharmaceuticals (NASDAQ:IDRA) Rating Reaffirmed

Idera Pharmaceuticals (NASDAQ:IDRA) just had their share rating of a ‘”Outperform”‘ issued by research analysts at Baird, who now has a $4 TP on the $382.47 million market cap company or a 127.27 % upside potential. This key information was disclosed to clients in an analyst note on Wednesday, 13 June.

It closed at $1.76 lastly. It is down 15.57% since June 13, 2017 and is uptrending. It has outperformed by 3.00% the S&P500.

Analysts await Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to report earnings on August, 6. They expect $-0.10 earnings per share, up 28.57 % or $0.04 from last year’s $-0.14 per share. After $-0.10 actual earnings per share reported by Idera Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $382.47 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

More notable recent Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) news were published by: Seekingalpha.com which released: “Idera Pharma’s IMO-8400 flunks mid-stage dermatomyositis study; shares down 13% premarket” on June 12, 2018, also Fool.com with their article: “Here’s Why Idera Pharmaceuticals Fell as Much as 15.4% Today” published on June 04, 2018, Benzinga.com published: “42 Biggest Movers From Yesterday” on June 13, 2018. More interesting news about Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) were released by: Seekingalpha.com and their article: “Idera Pharmaceuticals (IDRA) ASCO Investor Event Presentation – Slideshow” published on June 05, 2018 as well as Benzinga.com‘s news article titled: “41 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: June 12, 2018.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: